Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]

Malaria Journal

Volumn 4, Issue , 2005, Pages

  Meissner, Peter E ^a   Mandi, Germain ^b   Witte, Steffen ^a   Coulibaly, Boubacar ^b   Mansmann, Ulrich ^a,c   Rengelshausen, Jens ^a   Schiek, Wolfgang ^d   Jahn, Albrecht ^a   Sanon, Mamadou ^b   Tapsoba, Théophile ^b   Walter Sack, Ingeborg ^a   Mikus, Gerd ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Schirmer, Heiner ^a   Kouyaté, Bocar ^b   Müller, Olaf ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CENTRE DE RECHERCHE EN SANTÉ DE NOUNA   (Burkina Faso)

^c UNIVERSITY OF MUNICH   (Germany)

^d DSM Fine Chemicals Austria Nfg GmbH & Co KG   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CREATININE; METHYLENE BLUE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ARTICLE; BURKINA FASO; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HEPATITIS A; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; INFESTATION; JAUNDICE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POVERTY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RURAL POPULATION; SIDE EFFECT; SKIN DISEASE; SUBCUTANEOUS TISSUE; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

BURKINA FASO; CHILD, PRESCHOOL; CHLOROQUINE; DRUG THERAPY, COMBINATION; GLYCOGEN STORAGE DISEASE TYPE I; HUMANS; INFANT; MALARIA, FALCIPARUM; METHYLENE BLUE;

EID: 26844558146     PISSN: 14752875     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-4-45     Document Type: Article

References (40)

1. Amaral L, Viveiros M, Kristiansen JE: Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Trop Med Int Health 2001, 6:1016-1022.
2. Beutler E, Mitchell M: Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood 1968, 32:816-818.
3. Beutler E: G6PD deficiency. Blood 1994, 84:3613-3636.
4. Bloland PB, Ettling M, Meek S: Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ 2000, 78:1378-1388.
5. Breman JG, Alilio MS, Mills A: Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 2004, 71(Suppl 2):1-15.
6. Coulibaly B: Malaria-related studies on enzymopathies, methaemoglobin, and methylene blue. In Dissertation Heidelberg University; 2004.
7. Coulibaly B, Eubel J, Gromer S, Schirmer RH: Biochemistry-based health care research. Methylene blue, malaria, methaemoglobin, and malnutrition. In Health research in developing countries Edited by: Becher H, Kouyaté B. Springer Verlag Berlin Heidelberg; 2005:285-292.
8. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D: A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001, 344:257-263.
9. Ehrlich P: Chemotherapeutics: scientific principles, methods, and results. Lancet 1913, 182:445-451.
10. Färber PM, Arscott LD, Williams CH, Becker K, Schirmer RH: Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Letters 1998, 422:311-314.
11. Ferreira C: Sur l'emploi du bleu de méthylène dans la malaria infantile. Rev Ther Med Chir 1893:488-525.
12. Fleming AF, de Silva PS: G6PD deficiency. In Manson's Tropical Diseases Edited by: Cook GC, Zumla A. Elsevier Science Ltd, Edinburgh, UK; 2003:208-212.
13. Ginsburg, Golenser J: Glutathione is involved in the antimalarial action of chloroquine and its modulation affects drug sensitivity of human and murine species of Plasmodium. Redox Rep 2003, 8:276-279.
14. Guttmann P, Ehrlich P: Über die Wirkung des Methylenblau bei Malaria. Berliner Klinische Wochenschrift 1891, 28:953-956.
15. Janssen WJ, Dhaliwal G, Collard HR, Saint S: Clinical problem-solving. Why "why" matters. N Engl J Med 2004, 351:2429-2434.
16. Klemperer G: Grundriss der klinischen Therapie innerer Erkrankungen, 2. Auflage, Urban und Schwarzenberg, Berlin und Wien; 1924:34-35.
17. Kotea R, Kaeda JS, Yan SLK, Sem Fa N, Beesoon S, Jankee S, Ramasawmy R, Vulliamy T, Bradnock RW, Bautista J, Luzzatto L, Krishnamoorthy R, Mason PJ: Three major G6PD-deficient polymorphic variants identified among the Mauritian population. Br J Haematol 1999, 104:849-854.
18. Küpfer A, Aeschlimann C, Wermuth B, Cerny T: Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 1994, 343:763-764.
19. Lang T, Greenwood B: The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis 2003, 3:162-168.
20. Mandi G, Witte S, Meissner P, Coulibaly B, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Sanon M, Wust K, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer H, Kouyate B, Muller O: Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health 2005, 10:32-38.
21. Mayer M: Über die Wirkung von Methylenblau bei Malaria quartana. Dtsch Med Wochenschrift 1919, 45:1052-1053.
22. Meierjohann S, Walter RD, Müller S: Regulation of intracellular glutathione levels in erythrocytes infected with chloroquinesensitive and chloroquine-resistant Plasmodium falciparum. Biochem J 2002, 368:761-768.
23. Meissner P, Coulibaly B, Mandi G, Mansmann U, Witte S, Schiek W, Müller O, Schirmer RH, Mockenhaupt FP, Bienzle U: Diagnosis of red cell G6PD deficiency in rural Burkina Faso. Comparison of a rapid fluorescent enzyme test on filter paper with PCR based genotyping. Br J Haematol 2005 in press.
24. Modiano D, Luoni G, Sirima BS, Lanfrancotti A, Petrarca V, Cruciani F, Simpore J, Ciminelli BM, Foglietta E, Grisanti P, Bianco I, Modiano G, Coluzzi M: The lower susceptibility to Plasmodium falciparum malaria of Fulani of Burkina Faso (West Africa) is associated with low frequencies of classic malaria-resistance genes. Trans R Soc Trop Med Hyg 2001, 95:149-152.
25. Müller O, Becher H, Baltussen A, Ye Y, Diallo DA, Konate AT, Gbangou A, Kouyate B, Garenne M: Effect of zinc supplementation on malaria morbidity among West African children: a randomized double-blind placebo-controlled trial. BMJ 2001, 322:1567-1572.
26. Müller O, Traoré C, Kouyaté B, Becher H: Malaria morbidity, treatment seeking behaviour, and mortality in a cohort of young children in rural Burkina Faso. Trop Med Int Health 2003, 8:290-296.
27. Müller O, Traoré C, Kouyaté B: Clinical efficacy of chloroquine in young children with uncomplicated malaria - a community based study in rural Burkina Faso. Trop Med Int Health 2003, 8:202-203.
28. Nosten F, Brasseur P: Combination therapy for malaria. Drugs 2002, 62:1315-1329.
29. Ouedraogo JB, Dutheil Y, Tinto H, Traore B, Zampa H, Tall F, Coulibaly SO, Guiguemde TR: In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa). Trop Med Int Health 1998, 3:381-384.
30. Rengelshausen J, Burhenne J, Fröhlich M, Tayrouz Y, Singh SK, Riedel KD, Muller O, Hoppe-Tichy T, Haefeli WE, Mikus G, Walter-Sack I: Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharm 2004, 60:709-715.
31. Sarma GN, Savvides SN, Becker K, Schirmer M, Schirmer RH, Karplus PA: Glutathione reductase of the malarial parasite Plasmodium falciparum: Crystal structure and inhibitor development. J Mol Biol 2003, 328:893-907.
32. Schirmer RH, Coulibaly B, Stich A, Scheiwein M, Merkle H, Eubel J, Becker K, Becher H, Muller O, Zich T, Schiek W, Kouyate B: Methylene blue as an antimalarial agent. Redox Rep 2003, 8:272-276.
33. Sirima SB, Tiono AB, Konate A, Diarra A, Castelli F, Pinoges L, Mugittu K, Taylor WR, Olliaros PL: Efficacy of artesunate plus chloroquine for the treatment of uncomplicated malaria in children in Burkina Faso: a double-blind, randomized, controlled trial. Trans R Soc Trop Med Hyg 2003, 97:345-349.
34. Snow RW, Craig M, Deichmann U, Marsh K: Estimating mortality, morbidity and disability due to malaria among Africa's nonpregnant population. Bull World Health Organ 1999, 77:624-640.
35. Tinto H, Zoungrana EB, Coulibaly SO, Ouedraogo JB, Traore M, Guiguemde TR, Van Marck E, D'Alessandro U: Chloroquine and sulphadoxine-pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo-Dioulasso, Burkina Faso during a 3-year period 1998-2000. Trop Med Int Health 2002, 7:925-930.
36. Trape J: The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001, 64(suppl):12-17.
37. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK 2nd, Danis M, Greenwood BM, Anderson RM, Olliaro P: Averting a malaria disaster. Lancet 1999, 353:1965-1967.
38. WHO: World malaria situation 1994. Weekly Epid Rec 1997, 72:269-292.
39. WHO: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization, Geneva; 2003. WHO/HTM/RBM/2003.50
40. Winstanley P: Modern chemotherapeutic options for malaria. Lancet Infect Dis 2001, 1:242-250.